Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID... see more

TSXV:CLAS.H - Post Discussion

Claritas Pharmaceuticals Inc > 130 Million Shares of 500+ float ; Bought by Salzman Group📈
View:
Post by PowerofNow on Apr 06, 2021 3:30pm

130 Million Shares of 500+ float ; Bought by Salzman Group📈

Takes about 1200 people holding 500k shares to take out entire float !! HUGE insider ownership POP.

issuance of 130 million common shares of the Company to the Salzman Group.

Salzman  Group,  Ltd.,  an  Israeli corporation, and Salzman Group Pty Ltd., an Australian corporation (collectively the "Salzman Group"), and Kalytera Therapeutics, Inc. (the "Company"), whereby the Company may acquire a license to develop and commercialize R-107 with a license fee of US$1.2 million and the issuance of 130 million common shares of the Company to the Salzman Group.  Further considerations include *--a success fee of US $2 million based on certain milestone and additional milestone payments in stages in the cash amount of US$4,250,000 !!!!! --*
Comment by PowerofNow on Apr 07, 2021 2:25pm
Loving the LOW VOLUME. Proving that no one is selling @.04 cents this tight squeeze is going to be very interest !
Comment by 8CornerPocket on Apr 07, 2021 4:41pm
Between this squeeze and the Ontario court decision shared here earlier today I am smiling from ear to ear. Nice to see the courts identifying 'anonymous' keyboard hero's and holding them accountable for defamation. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities